(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.77%.
Praxis Precision Medicines's revenue in 2026 is $0.On average, 21 Wall Street analysts forecast PRAX's revenue for 2026 to be $72,763,600, with the lowest PRAX revenue forecast at $0, and the highest PRAX revenue forecast at $355,370,732. On average, 20 Wall Street analysts forecast PRAX's revenue for 2027 to be $9,697,910,324, with the lowest PRAX revenue forecast at $3,831,101,123, and the highest PRAX revenue forecast at $19,709,456,855.
In 2028, PRAX is forecast to generate $31,809,681,134 in revenue, with the lowest revenue forecast at $14,115,023,276 and the highest revenue forecast at $58,601,182,948.